

Date : 21st May, 2018.

To
BSE Ltd.,
PJ Towers,
Dalal Street,
Mumbai - 400 001.

Sub. : **Newspaper Notice regarding Board Meeting and Closure of Trading Window.**

Reg. : **Clause 47(1)(a) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.**

Dear Sir,

Kindly find enclosed copies of publication of Notice of Board Meeting scheduled on Tuesday, 29th May, 2018. The notice appeared in two Newspapers Viz.:

- (1) The Free Press Journal (English) and
- (2) Navshakti (Marathi)

both dated 19th May, 2018.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Ltd.,



(Ashish R. Shah)
Company Secretary.

★ JENBURKT

Jenburkt Pharmaceuticals Ltd.

CIN: L24230MH1985PLC036541
Regd. Office: Nirmala Apartments,
93, J.P.Road, Andheri(W), Mumbai-58
Email: investor@jenburkt.com
Tel.: 67603603, Fax: 66943127

NOTICE

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held at the Registered Office of the Company on Tuesday, 29th May, 2018, inter-alia, to consider and approve the Company's audited financial results for the Quarter and Financial Year ended on 31st March, 2018 and to consider recommendation of final dividend, if any.

The said notice may be accessed at Company's website, viz. www.jenburkt.com or at BSE Ltd.'s website, viz. www.bseindia.com.

By Order of the Board
for Jenburkt Pharmaceuticals Ltd.

Ashish R Shah
Company Secretary

Place : Mumbai
Date : 18th May, 2018

★ JENBURKT

Jenburkt Pharmaceuticals Ltd.

CIN: L24230MH1985PLC036541
Regd. Office: Nirmala Apartments,
93, J.P.Road, Andheri(W), Mumbai-58
Email: investor@jenburkt.com
Tel.: 67603603, Fax: 66943127

NOTICE

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held at the Registered Office of the Company on Tuesday, 29th May, 2018, inter-alia, to consider and approve the Company's audited financial results for the Quarter and Financial Year ended on 31st March, 2018 and to consider recommendation of final dividend, if any.

The said notice may be accessed at Company's website, viz. www.jenburkt.com or at BSE Ltd.'s website, viz. www.bseindia.com.

By Order of the Board
for Jenburkt Pharmaceuticals Ltd.

Ashish R Shah
Company Secretary

Place : Mumbai
Date : 18th May, 2018